The U.S. Justice Department said Tuesday that drug maker Pfizer Inc. will pay almost $491 million to resolve an investigation into illegal marketing of the organ transplant drug Rapamune by Wyeth, a company Pfizer later acquired. The drug was targeted at African American patients and the case arose out of a whistleblower complaint. The lawsuits, which were filed by a pair of former Wyeth sales reps and a pharmacist, also charged Wyeth offered off-label studies, abstracts and lists of studies to use when marketing Rapamune for off-label use, along with kickbacks to doctors and hospitals in the form of donations, grants and speaker fees to prescribe the drug off-label. The FDA, by the way, warned against off-label use in 2004 and 2007.
More on the settlement here